Drug surveillance data in a Canadian hospital

Area of Science:

• Pharmacovigilance
• Drug Safety Monitoring

Background:

• Hospital-based drug surveillance programs are crucial for identifying adverse drug reactions (ADRs).
• International comparisons help validate surveillance data and identify global trends in drug safety.

Purpose of the Study:

• To compare drug exposure and adverse reaction rates between a Canadian hospital-based surveillance program and international centers.
• To identify factors influencing drug use and ADRs, including drug types and patient demographics.
• To assess the role of autopsy in detecting drug-related deaths.

Main Methods:

• Comparative analysis of drug surveillance data from Canadian, US, and Israeli centers.
• Review of drug usage patterns, focusing on symptomatic relief medications.
• Analysis of demographic data (gender) in relation to drug exposure and ADRs.
• Examination of autopsy findings to correlate drug events with causes of death.

Main Results:

• No significant differences in drug exposure or adverse reaction rates were observed between the Canadian center and international sites.
• Drugs for symptomatic relief were frequently utilized in the Canadian cohort.
• Women experienced higher rates of drug exposure and adverse reactions compared to men.
• Commonly prescribed drugs were implicated in life-threatening and fatal adverse reactions.
• Autopsy findings proved valuable in uncovering previously unrecognized links between drug administration and mortality.

Conclusions:

• Hospital-based drug surveillance programs demonstrate consistent findings across different international settings.
• Demographic factors, such as gender, influence drug exposure and ADR risk.
• Commonly used drugs pose significant risks, necessitating robust monitoring systems.
• Autopsy plays a vital role in post-mortem identification of adverse drug events.
• Both voluntary reporting and intensive monitoring are essential components of effective pharmacovigilance.